Clinical trials: Transfusional Iron Overload
Thalassemia, Iron Overload
Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload
Thalassemic patients often suffer from iron overload due to frequent blood transfusion. Oral iron chelators reduce iron overload in transfusion dependent patients.
- Conditions
- Thalassemia, Iron Overload, Transfusion Related Complications
- Trial name
- NCT01369719
- Testing
- osveral, Desferal
- Where
- Iran
- Volunteers
- 138 people
- Sponsor
- Hormozgan University of Medical Sciences
Iron Overload
Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis
This study employed a prospective, single-arm, global multi-center interventional open-label, non-randomized design to identify and assess safety profile of the crushed deferasirox FCT when administered up to 24 weeks in…
- Trial name
- MIMAS (NCT03372083)
- Testing
- Deferasirox
- Where
- 10 sites in Egypt, Italy and 5 more
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Heart Disease
Deferoxamine for the Treatment of Hemochromatosis
When patients receive repeated blood transfusions the level of iron in the patient s blood can rise. When iron is processed in the body a protein known as hemosiderin can begin collecting in the organs.
- Conditions
- Diabetes Mellitus, Heart Disease, Hemochromatosis, Thalassemia
- Trial name
- NCT00001203
- Where
- United States
- Volunteers
- 151 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
MRI Scans
Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy
The overall goal of this research is to help develop a new magnetic resonance (MR) method, Quantitative Susceptibility Mapping (QSM), to improve the measurement of liver iron concentrations without the need for a liver biopsy.
- Trial name
- NCT04171635
- Testing
- Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI), R2* Magnetic Resonance Imaging (MRI)
- Where
- 2 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Hemochromatosis, Myelodysplastic Syndromes
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
Hypothesis: Deferasirox can be used as a therapeutic agent to deplete the liver, heart and bone marrow of excess iron in patients with iron overload caused by myelodysplastic syndrome (MDS) and hemochromatosis (HC.
- Trial name
- DefeHEMY (NCT01892644)
- Testing
- Deferasirox, Venesection
- Where
- Norway
- Volunteers
- healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
Transfusional Iron Overload
Active Drug Surveillance Program of Ferriprox Use
Observational, open label, prospective, multi-center, post-marketing drug surveillance program.
- Trial name
- NCT01838291
- Where
- 14 sites in Cyprus, Egypt and 3 more
- Volunteers
- 294 people
- Sponsor
- ApoPharma
Myelodysplastic Syndromes, Transfusion Dependent Iron Overload
Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload
The purpose of this study is to investigate the effects of iron chelation using deferasirox in low and INT-1 risk (referring to the international prognostic scoring system, IPSS) MDS patients who show signs of iron overload due…
- Trial name
- NCT00481143
- Testing
- ICL670/Deferasirox
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
Beta-Thalassemia
Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia
A clinical trial designed to compare the safety and iron excretion properties of desferoxamine (DFO) and deferitrin (GT56-252), an experimental oral iron chelator.
- Trial name
- NCT00069862
- Testing
- Deferitrin (GT56-252), desferoxamine (DFO)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Genzyme, a Sanofi Company
Myelodysplastic Syndromes, Iron Overload
Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
Thirty patients were to be enrolled and 24 patients were actually enrolled into this open-label, single-arm trial designed to assess the safety and tolerability of oral deferasirox in adult transfusion dependent myelodysplastic…
- Trial name
- NCT00117507
- Testing
- Deferasirox
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Myelodysplastic Syndrome, Iron Overload
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
The purpose of this trial is to examine the safety and efficacy of deferasirox in patients with Myelodysplastic Syndrome (MDS) and chronic iron overload from blood transfusions.
- Trial name
- NCT00110266
- Testing
- Deferasirox
- Where
- 48 sites in United States, Canada
- Volunteers
- 176 people
- Sponsor
- Novartis Pharmaceuticals
Transfusional Iron Overload, Thalassemia Major
High-Tc Susceptometer to Monitor Transfusional Iron Overload
The proposed research project will continue the application and development of a new method (biomagnetic susceptometry) that measures magnetic fields to determine how much iron is in the liver.
- Conditions
- Transfusional Iron Overload, Thalassemia Major, Sickle Cell Disease, Myelodysplastic Syndromes
- Trial name
- NCT01241357
- Testing
- Hepatic biomagnetic susceptibility measurement
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Columbia University
Anemia (Iron-Loading), Beta-Thalassemia
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
To determine whether deferoxamine prevented the complications of transfusional iron overload.
- Conditions
- Anemia (Iron-Loading), Beta-Thalassemia, Hematologic Diseases, Hemoglobinopathies
- Trial name
- NCT00000595
- Testing
- deferoxamine
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myelodysplastic Syndrome, Thalassemia
This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.
This study will evaluate the efficacy and safety of deferasirox in patients with MDS, thalassemia and rare anemia patients with transfusion iron overload.
- Trial name
- NCT01250951
- Testing
- Deferasirox
- Where
- 2 sites in Russia
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Beta-Thalassemia
Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
The purpose of this study is to deterimine if the new orally active iron chelator, ICL670, is as effective and as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood…
- Trial name
- NCT00061750
- Testing
- ICL670, deferoxamine
- Where
- 7 sites in United States
- Volunteers
- 595 people
- Sponsor
- Novartis Pharmaceuticals
Transfusional Iron Overload
Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload
A 1-year randomized Phase IIa core trial followed by a prolongation of 5 to 9 months was conducted to investigate the efficacy and safety of deferasirox in patients aged ≥ 18 years with transfusion-dependent iron overload.
- Trial name
- NCT00379483
- Testing
- Deferasirox
- Where
- 4 sites in Italy
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphocytic Leukemia, Acute Myeloid Leukemia
Transfusional Iron Overload Among Leukemia Survivors
Red cell transfusions are an important part of supportive cancer therapy. The iron in the transfused blood may build up in the body since the human body has no way to get rid of extra iron.
- Trial name
- NCT01965171
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- St. Jude Children's Research Hospital
Iron Overload
Changes in Pituitary Iron and Volume With Deferasirox
Despite continuing advances in iron chelation therapy, iron toxicity of endocrine glands, particularly the pituitary gland, remains common in patients with transfusion dependent anemias.
- Trial name
- NCT01376622
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Los Angeles
Myelodysplastic Syndrome, Transfusional Iron Overload
Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
The objective of the study is to evaluate and compare the frequency and severity of GI adverse events in different dose administration regimens.
- Trial name
- MACS1574 (NCT01326845)
- Testing
- Deferasirox
- Where
- 10 sites in France, Italy and 2 more
- Volunteers
- 12 people
- Sponsor
- Novartis Pharmaceuticals
Transfusional Iron Overload, Beta-Thalassemia
Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload
This is an open-label study to assess the pharmacokinetics, safety, efficacy and tolerability of SSP-004184AQ. The study consists of two phases: the pharmacokinetic phase, using a single 16 mg/kg dose of SSP-004184AQ; and the…
- Trial name
- NCT01363908
- Testing
- SPD602
- Where
- 9 sites in United States, Canada and 3 more
- Volunteers
- 30 people
- Sponsor
- Shire
Myelodysplastic Syndromes, Hemosiderosis
Safety, Tolerability, and Efficacy of Deferasirox in MDS
Open label, single arm study on Deferasirox treatment in MDS patients with chronic transfusional hemosiderosis. Patients receive daily oral dosis of Deferasirox in order to eliminate the quantity of iron administered during…
- Trial name
- NCT00469560
- Testing
- Deferasirox
- Where
- 17 sites in Italy
- Volunteers
- 158 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto